863877-82-1

Basic information

• Product Name: 1H-Benzimidazole-1-carboxylic acid, 6-methyl-, 1,1-dimethylethyl ester
• CAS NO: 863877-82-1
• Molecular Formula: C13H16N2O2
• Mol File: 863877-82-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1H-Benzimidazole-1-carboxylic acid, 6-methyl-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-1-carboxylic acid, 6-methyl-, 1,1-dimethylethyl ester(863877-82-1)
• EPA Substance Registry System: 1H-Benzimidazole-1-carboxylic acid, 6-methyl-, 1,1-dimethylethyl ester(863877-82-1)

Safety Data

• Hazardous Substances Data: 863877-82-1(Hazardous Substances Data)

Usage

Ester derivative

1H-Benzimidazole-1-carboxylic acid, 6-methylThe compound is derived from 6-methyl-1H-benzimidazole-1-carboxylic acid by replacing the hydroxyl group with an ester group.

Methyl ester

1,1-dimethylethyl ester The ester group is a 1,1-dimethylethyl ester, which is a type of alkyl ester.

Usage in organic synthesis

Building block This compound is used as a building block in organic synthesis for the synthesis of various biologically active molecules.

Application in pharmaceutical research

Drug discovery and development The compound has potential applications in drug discovery and development due to its unique chemical structure and reactivity.

Production of agrochemicals and fine chemicals

The compound is also used in the production of agrochemicals and other fine chemicals.

Synthesis of compounds with diverse properties and applications

The compound serves as a valuable intermediate for the synthesis of a wide range of compounds with different properties and applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 614-97-1 5-methylbenzimidazole 

Downstream Products

• 226250-03-9 tert-butyl 6-(bromomethyl)-1H-benzo[d]imidazole-1-carboxylate 
• 1037207-08-1 tert-butyl 5-(bromomethyl)-1H-benzo[d]imidazole-1-carboxylate 

Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Tetracyclic Indole Derivatives, compositions comprising at least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.